Report an error   

Submitted: 22 February 2013 Modified: 27 June 2017
HERDIN Record #: PCHRD13022214265948

Oral pharmacological treatment of X-linked dystonia parkinsonism: Successes and failures.

1Roland Dominic G. Jamora,
2Roland Dominic G. Jamora,
3Cid Czarina E. Diesta,
4Paul Matthew D. Pasco,
5Lillian V. Lee
Department of Neurosciences, College of Medicine - Philippine General Hospital - University of the Philippines-Manila,
Movement Disorders Center and Section of Neurology, International Institute for Neurosciences - St. Luke's Medical Center,
Philippine Movement Disorder Surgery Center - Cardinal Santos Medical Center,
Asian Hospital and Medical Center,
Child Neuroscience Center - Philippine Children's Medical Center


There is a paucity of published literature on the different oral medications tried for X-linked dystonia parkinsonism (XDP). In practice, most XDP patients are tired on medication typically used for patients with generalized dystonia. These drugs include anticholinergic agents, baclofen, clonazepam and other ben-zodiazepines, tetrabenazine, and clozapine. Although several articles have shown that these classess of drugs are beneficial for patients with generalized dystonia, none been systematically studied specifically for XDP patients. We are currently conducting the first randomized, placebo-controlled trial on the medications that have been used in XDP.

Publication Type:
Publication Sub Type:
Journal Article, Original
The Philippine Journal of Neurology
Publication Date:
August 2012
Philippine Neurological Association

LocationCall NumberAvailable FormatAvailability
Philippine Council for Health Research and Development Library Box no.54 Fulltext Print Format (Request Document)
1. Ayd, F J. "A survey of drug-induced extrapyramidal reac-tions." Journal of American Medical Association 175(12): 1054-1060, 1961
2. Evidente, V G. "Zolpidem improves dystonia in "Lubag" or X-linked dystonia- parkinsonism syndrome." Neurology 58, 662-663, 2002
3. Fahn, S . "Treatment of dystonia with high dosage anticholin-ergic medication." Neurology 29, 605, 1979
4. Gordon, M F, Diaz-Olivo, R , Hunt, A L, Fahn, S . "Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders." Movement Disorders 8(4): 484-488, 1993
5. Greene, P , Shale, H , Fahn, S . "Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs" Movement Disorders 3(1): 46-60, 1988
6. Horn, S , Comella, C L. "Pharmacologic treatment of generalized dystonia. In M. F. Brin, C. L. Comella & Oral Treatment of XDP 21 J. Jankovic (eds), Dystonia: Etiology, Clinical Features, and Treatment." Philadephia, PA: Lippincott Williams & Wilkins , 71-77, 2004
7. Jankovic, J , Beach, J . "Long-term effects of tetrabenazine in hyperkinetic movement disorder." Neurology 48, 358-362, 1997
8. Karp, B I, Goldstein, S R, Chen, R , Samii, A , Bara-Jimenez, W , Hallet, M . "An open trial of clozapine for dystonia. Move-ment Disorders" Move-ment Disorders 14(4): 625-657, 1999
9. Lee, L V, Munoz, E L, Tan, K T, Reyes, M T. "Sex-linked recessive dystonia parkinsonism of Panay, Philippines (XDP)." Molecular Pathology 54(6): 362-368, 2001
10. Lee, L V, Pascasio, F M, Fuentes, F D, Viterbo, G H. "Torsion dystonia in Panay, Philippines. Advances in Neurology" 14, 137-151, 1976
11. Teravainen, H , Calne, S , Burton, K , Beckman, J , Calne, D B. "Efficacy of dopamine agonists in dystonia." Advances in Neurology 50, 571-577, 1988